Zoetis presents pipeline with major market approvals expected annually for next several years
ZTS•Zoetis expects major-market approvals each year for several years, with product launches targeted from 2026 onward; the global animal health market is forecast to grow from about $50 billion in 2024 to $85 billion-$95 billion by 2035.
1. Pipeline and market outlook
Zoetis expects long-acting Cytopoint in 2026 and a renal monoclonal antibody therapy in 2027, followed by oncology monoclonal antibody therapies in 2028-2029. Obesity and anxiety treatments are targeted for 2030 onward. The company said its focused strategy aims to return Librela to growth in the osteoarthritis pain market.
